CD5L and type 2 diabetes mellitus: Clinical studies showed that IGFBP-3 is down-regulated in Type 2 Diabetes patients with renal disfunction, and predict future renal decline in people with type 2 diabetes combined with apoA4 and CD5L (Peters et al., 2017; Peters et al., 2019).